Publications by authors named "David Pinato"

Claim this Profile
O
Oncolytic virotherapy to reverse therapeutic resistance in advanced liver cancer.
David J Pinato

J Hepatol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma.
Giuseppe Cabibbo, Ciro Celsa, Sherrie Bhoori, Thomas Reiberger, David James Pinato

J Hepatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers.
Margherita Rimini, Lorenzo Fornaro, Masafumi Ikeda, Oluseyi Abidoye, Jessica Lucchetti, David J Pinato

Liver Int· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study.
Pasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, Ciro Celsa, Claudia A M Fulgenzi, David J Pinato

JHEP Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Host-related Determinants of Response to Immunotherapy in Non-small Cell Lung Cancer: The Interplay of Body Composition, Metabolism, Sex and Immune Regulation.
Valentina Santo, Leonardo Brunetti, Federica Pecci, Marianna Peroni, Giulia Barnini, David James Pinato

Curr Oncol Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interpreting immunogenicity in oncology clinical trials.
Peter R Galle, Martin Reck, David J Pinato, Rosario Garcia-Campelo, Richard S Finn

Cancer Treat Rev· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy in advanced hepatocellular cancer: The last piece of the puzzle.
David J Pinato

J Hepatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Probiotic supplement exposure and outcomes of patients with non-small cell lung cancer treated with first-line atezolizumab therapy: Pooled analysis of individual patient data from five randomized control trials.
Kazuki Takada, Mototsugu Shimokawa, Alessio Cortellini, David J Pinato, Fumitaka Mizuki

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.
Alessio Cortellini, Edoardo Garbo, Giulia La Cava, Fabrizio Citarella, Valentina Santo, David J Pinato

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatocellular carcinoma in people living with HIV.
Claudia A M Fulgenzi, Alessia Dalla Pria, Alberto Giovanni Leone, Ciro Celsa, Giuseppe Cabibbo, David James Pinato

J Hepatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.
Kenneth Sooi, Tuan Zea Tan, Jae-Weon Kim, Jung Yun Lee, Byoung-Gie Kim, David J Pinato

Br J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis.
Ciro Celsa, Gabriele Di Maria, Pasquale Lombardi, Antonio D'Alessio, Claudia A M Fulgenzi, David James Pinato

JAMA Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Bernhard Scheiner, Pasquale Lombardi, Antonio D'Alessio, Gwangil Kim, Masoud Tafavvoghi, David J Pinato

J Immunother Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: "A role for non-selective beta-blockers in preventing liver decompensation in patients with hepatocellular carcinoma undergoing systemic therapy": Advancing clinical trial design and patient care in hepatocellular carcinoma.
Ciro Celsa, David James Pinato, Giuseppe Cabibbo

J Hepatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma.
Amit G Singal, Riad Salem, David J Pinato, Anjana Pillai

Gastroenterology· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.
Alessio Cortellini, Valentina Santo, Leonardo Brunetti, Edoardo Garbo, David J Pinato

J Immunother Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes.
Dimitra Rafailia Bakaloudi, Rafee Talukder, Thomas Enright, Jacob B Leary, Dimitrios Makrakis, David J Pinato

Clin Genitourin Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of GLP-1 receptor agonist-induced weight loss on 22 cancers in the next ten years using a Markov state-transition model - A UK weight and wellness cancer landscape analysis.
Jiawen Dong, Thomas Starkey, Vinton W T Cheng, James Clark, David J Pinato

Cancer Epidemiol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence.
Giulia Francesca Manfredi, Claudia Angela Maria Fulgenzi, Ciro Celsa, Bernardo Stefanini, Antonio D'Alessio, David J Pinato

JHEP Rep· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma.
Amin H Nassar, Chul Kim, Tolulope Adeyelu, Elias Bou Farhat, Hassan Abushukair, David J Pinato

Nat Commun· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study.
Alessandro Vitale, Jung Sun Kim, Giuseppe Cabibbo, Andrea Casadei-Gardini, Massimo Iavarone, David J Pinato

Liver Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep sequencing of circulating tumour DNA as a biomarker of clinical outcome to transarterial chemoembolisation in hepatocellular carcinoma.
Rohini Sharma, Sultan N Alharbi, Ksenia Ellum, Leila Motedayen-Aval, Andrea Casadei-Gardini, David J Pinato

NPJ Precis Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi's Sarcoma.
Claudia A M Fulgenzi, Alessia Dalla Pria, Alberto Giovanni Leone, Maria Martinez, Elena Ferrer Martinez Del Peral, David J Pinato

BMC Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The present and the future of immunotherapy in hepatocellular carcinoma and biliary tract cancers.
Giuseppe Cabibbo, Lorenza Rimassa, Angela Lamarca, Gianluca Masi, Bruno Daniele, David James Pinato

Cancer Treat Rev· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders.
Kylie Fletcher, Marc Machaalani, Razane El Hajj Chehade, Amin H Nassar, Rashad Nawfal, David J Pinato

JAMA Netw Open· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis